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Abstract 
Introduction: The Australian Pharmaceutical Benefits Scheme (PBS) provides universal access to 
subsidised medicines. In 2013, statins as a class had the highest expenditure on the PBS. 
Objectives: To assess the influence of policies and drivers affecting PBS statin utilisation and 
expenditure between 1992 and 2013. Methods: Analyses conducted from 1992 to 2013 and over 
three distinct time periods, including monthly expenditure/prescription, annual utilisation (calculated as 
Defined Daily Doses/1000 inhabitants/day) and statin strengths dispensed. Results: The major driver 
of increased PBS expenditure for statins was increased volumes. After adjusting for inflation, the 
average PBS expenditure on statin prescriptions was the major negative driver. Other influential 
drivers included the increased use of newer statins and increased strength of statins dispensed. 
Discussion: Whilst the inflation-adjusted reimbursed price of statins decreased, increased utilisation, 
including increased use of patented statins, increased total statin expenditure. Successful measures 
adopted by other countries could be applied to Australia to decrease total medicines expenditure. 
 
Key words: Australia, demand-side measures, drug utilisation research, generics, guidelines, 
pharmaceutical expenditure, prices, statins 
 
Background 
 
In 2013, cardiovascular disease was the largest cause of death globally, including within Australia [1]. 
The use of lipid lowering medicines to treat high blood cholesterol levels and reduce cardiovascular 
disease has increased appreciably over the last decade [2], helped by guidelines endorsing their use 
following multiple studies demonstrating a reduction in morbidity and mortality [3-8]. In 2011, Australia 
had one of the highest consumptions per capita of lipid lowering medicines (137 Defined Daily Doses 
(DDD) per 1,000 people per day) compared to other Organisation for Economic Co-operation and 
Development (OECD) countries (OECD average 91 DDD per 1,000 people per day) [2, 8]. In 2013, 
lipid lowering medicines contributed the highest costs of any Anatomical Therapeutic Classification 
(ATC) drug group to the Australian government at AUD 1.33 billion overall, representing an increase 
of 52% from 2002 where total spending on this group was AUD 873.7million (in 2013 AUD) [9, 10]. 
Notably, the class of statins accounted for 90% of overall spending on lipid lowering medicines in 
2013 [9]. 
 
Several studies have shown that the prices for statins have been higher in Australia compared to 
other countries [11-13]. In early 2012, the wholesale price of simvastatin 40 mg in Australia was the 
most expensive when compared with 13 other OECD countries, and was still the third most expensive 
after a price decrease in 2012 [11]. In 2011-12, the price of atorvastatin was 96% higher in Australia 
than in New Zealand [12]. 
 
In addition to prices, the relative utilisation of cheaper off-patent generic statins compared to more 
expensive patent-protected statins also had a strong impact on total expenditure. Simvastastin and 
pravastatin were the first statins marketed in Australia, and lost patent protection in 2004 and 2005 
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respectively. Atorvastatin and rosuvastatin remained patent protected until 2012 and 2013 
respectively. The relative utilisation of patent-protected statins was shown to be greater in Australia 
than in the USA and some European countries with active policies to enhance the prescribing of 
generic statins [13, 14]. In the USA, only approximately 35% of the total statin market share was 
accounted for by patent-protected atorvastatin and rosuvastatin four years after simvastatin patent 
expiry [15]. In Germany, patented statins accounted for just 2.4% of total statins following the 
introduction RIDµMXPER¶FODVVIRUDOOVWDWLQV [14, 16]. In three countries with multiple policies to 
enhance the prescribing of generic versus patented statins, patented statins accounted for 21% of 
total statins in Sweden in 2007, 39% in the Netherlands in 2010 and 40% in Scotland in 2010 [8, 14, 
17]. In contrast, four years after the simvastatin patent expiry in Australia, 70% of all statin 
prescriptions on the PBS were for the more expensive patented atorvastatin and rosuvastatin [13]. 
This difference in utilisation patterns for statins was estimated to have cost Australia AUD$1.1 billion 
compared to potential expenditure  if statin utilisation patterns in Australia more closely resembled 
those in England in those four years [13].  
 
Expenditure on statins was lowered in the Netherlands, Sweden and the UK by the price of generic 
simvastatin being as low as 2% to 4% of the price prior to patent expiry through government 
interventions. These include preference pricing policies in the Netherlands, compulsory generic 
substitution with the lowest price molecule in Sweden, and high international non-proprietary name 
(INN) prescribing coupled with transparency in the pricing of generics in the UK [8, 17-19]. This 
expenditure control was helped by health authorities across Europe typically viewing all statins as 
therapeutically equivalent at appropriate doses [8, 16, 17, 20-22]. Recent studies including one in 
Australia have shown that lower out of pocket costs for patients increase compliance, which can lead 
to lower cardiovascular event rates [23, 24]. 
 
In Australia, a number of supply side and demand side policies have been implemented to control 
expenditures on medicines listed on the Pharmaceutical Benefits Scheme (PBS), the national public 
pharmaceutical insurance scheme. Since 2005, new major pricing policies have included a 16% price 
reduction for medicines upon the entry of the first generic version, separation of the PBS into two 
different formularies (F1 containing non-equivalent patent protected medicines and F2 containing 
medicines with equivalents or generics) and the introduction of price disclosure [12, 25]. Price 
disclosure for medicines on F2 mandates that manufacturers provide data on the ex-manufacturer 
price of medicines to the government, with adjustments to the PBS price if the average weighted 
disclosed price of medicines is more than 10 per cent cheaper than the ex-manufacturer price on the 
PBS.  
 
Demand side policies have also been implemented for prescribers, pharmacists and patients. There 
are brand or therapeutic group premiums paid by the patient for brands with higher prices than the 
lowest priced brand [26, 27].  
 
Generic substitution is allowed at the pharmacy level, with fees paid to pharmacies to dispense 
medicines which do not attract extra price premiums and there are public information campaigns run 
by the National Prescribing Service (NPS) [28, 29].  These policies have been collated under the 4 Es 
± Education, Economics, Engineering and Enforcement [30], with this approach successfully used 
within and across countries and medicine classes to compare and contrast the influence of different 
demand side measures on both new and established medicines [14, 17, 31-35]. Policies influencing 
the prescribing of generics versus originators in Australia are included in Table 1. In contrast, the 
Pharmaceutical Benefits Advisory Committee (PBAC, the committee which assesses listing of 
medicines on the PBS) considered atorvastatin and rosuvastatin to have a better efficacy than 
simvastatin on two different occasions, first in July 2005 and then in 2012 during a review of statin 
therapies [36].  
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Table 1 ± Australian demand side policies to influence the prescribing of generics 
 
Category Definition Examples in Australia 
Education Programs influencing the 
prescribing and dispensing of 
generic medicines 
Public campaigns regarding generic medicines 
efficacy and safety 
 
Engineering Organisational and 
managerial interventions that 
influence change 
Prescribing software that automatically allows for 
brand substitution 
Pharmacist initiated brand substitution allowed 
Economics Financial interventions to 
promote the use of cheaper 
medicines 
Brand price premiums for a number of medicines 
Financial incentive to pharmacist to dispense 
medicines without brand price premiums 
Enforcement Regulations which include 
those enforced by law 
None currently in Australia 
 
A number of studies have assessed the prices and usage of statins in Australia compared with other 
countries [12, 13]. However, all these studies had a cross-sectional design and did not examine the 
impact of policies over time. This study aimed to assess the influence of policies and drivers affecting 
PBS statin utilisation and expenditure between 1992 and 2013. It also examined the drivers of statin 
expenditure with regard to the relative effect of prices, usage, and changes to strengths and types of 
statins used over time. The large utilisation and total cost to the PBS for supplying statins makes them 
an excellent case study for examining the effects of government interventions in the medicines market 
in Australia. 
 
Methods 
 
x Funding timeline of statins 
A review of funding decisions relating to the listing and pricing of statins on the PBS was undertaken 
using PBAC outcome summary documents, past versions of the PBS schedule and Department of 
Health documents [36-39]. A timeline encompassing all the decisions about statins on the PBS 
including the listing, price changes and restrictions on availability was documented. 
 
x Expenditure and volume data sources 
Total expenditure and prescription data were obtained from the PBS items report website [40]. This 
database covers all prescription volumes and expenditure for medicines that are reimbursed by the 
Australian Government, but does not cover under co-payment nor private prescriptions [41]. Total 
statin expenditure per month from 1992 to 2013 was calculated and adjusted for inflation. All dollar 
values were adjusted for inflation using the Consumer Price Index for each quarter and linear 
interpolation across every three month period was applied [42].  
 
x Drivers of PBS statin expenditure 
Cost driver analysis was conducted to determine the factors which impact upon total statin 
expenditure. The drivers of statin expenditure on the PBS were estimated by adapting the 
methodology from the Patented Medicine Prices Review Board (PMPRB) in Canada [43]. The effect 
of each specific driver can be captured through this methodology as it compares two time periods and 
isolates the effect of the change in a specific factor by holding the other factors constant at the base-
period value [43]: ܺሺݐሻ ൌ ෍ ݌ሺ݅௦ǡ௠ǡ ݐሻ ൈ௜ೞǡ೘ ߙ൫݅௦ǡ௠ǡ ݐ൯ ൈ ߚሺ݅௠ǡ ݐሻ ൈ ܳሺݐሻ ݐ: Time period ܺሺݐሻ: Total expenditure in time period t ݌ሺ݅௦ǡ௠ǡ ݐሻ: The average expenditure per prescription for product i on the PBS of a certain strength-form 
combination (s) and molecule (m) in time period t ߙ൫݅௦ǡ௠ǡ ݐ൯: The share of quantity for product i over the sum of quantities for all medicines with the same 
active ingredient in time period t ߚሺ݅௠ǡ ݐሻ: The share of the sum of quantities for statins with the same active ingredient over the sum of 
quantities for all statins in time period t ܳሺݐሻ: Total number of prescriptions in time period t  
Changes in PBS expenditure on statins are attributed to the drivers which are summarised below: 
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x Price effect: captures the impact of changes to the price the Government pays for statins 
x Strength effect: captures the impact of shifting utilisation towards different strengths or 
formulations of a molecule (active ingredient) 
x Switch effect: captures the impact of shifts in market shares between statins that are available in 
both time periods analysed 
x New statin effect: captures the impact of shifts in utilisation of statins that have entered the 
market in the second time period and were not present in the first time period 
x Volume effect: captures the impact of changes in the number of prescriptions dispensed to the 
population 
 
Between two time periods the difference in total expenditure: ܺሺ ?ሻ െ ܺሺ ?ሻ= 
x Price effect  ? ሾ݌ሺ݅௦ǡ௠ǡ  ?ሻ െ ݌ሺ ௦݅ǡ௠ǡ  ?ሻሿ ൈ௜ೞǡ೐ǡ೘ ߙ൫݅௦ǡ௠ǡ  ?൯ ൈ ߚሺ௠݅ ǡ  ?ሻ ൈ ሺܳ ?ሻ ൅ 
x Strength effect   ? ݌ሺ݅௦ǡ௠ǡ  ?ሻ ൈ ሾߙ൫ ௦݅ǡ௠ǡ  ?൯ െ ߙ൫ ௦݅ǡ௠ǡ  ?൯ሿ ൈ ߚሺ௠݅ǡ  ?ሻ ൈ ሺܳ ?ሻ ൅௜ೞǡ೐ǡ೘   
x Switch effect   ? ݌ሺ݅௦ǡ௠ǡ  ?ሻ ൈ ߙ൫ ௦݅ǡ௠ǡ  ?൯ ൈ ሾߚሺ௠݅ǡ  ?ሻ െ ߚሺ௠݅ǡ  ?ሻሿ ൈ ሺܳ ?ሻ ൅௜ೞǡ೐ǡ೘   
x New statin effect  ? ݌ሺ݅௦ǡ௠ǡ  ?ሻ ൈ ߙ൫ ௦݅ǡ௠ǡ  ?൯ ൈ ߚሺ௠݅ǡ  ?ሻ ൈ ሺܳ ?ሻ ൅௜ೞǡ೐೙ǡ೘    
x Volume effect   ? ݌ሺ݅௦ǡ௠ǡ  ?ሻ ൈ ߙ൫ ௦݅ǡ௠ǡ  ?൯ ൈ ߚሺ௠݅ǡ  ?ሻ ൈ ሾ ሺܳ ?ሻ െ ܳሺ ?ሻሿ௜ೞǡ೘   
 
Individual effects derived from the use of this methodology may explain most but not all the changes 
in total PBS expenditure for statins. The effect of each factor is calculated with the assumption that all 
other factors remain unchanged over the time period analysed. In reality, multiple factors change 
simultaneously, creating residual effects or cross effects [43]. 
 
An analysis of drivers was conducted firstly over the whole period from 1992 to 2013. In addition, 
three shorter-period analyses were conducted. From 1992 to 1996, the introduction of new statins on 
the PBS may have obscured and distorted the drivers, and so was not separately analysed. The 
shorter-period analyses were thus conducted consecutively from 1997. The first of these shorter time 
periods was from 1997 to 2005 and assesses the impact of the introduction of atorvastatin compared 
to the other statins. The second such time period was from 2006 to 2010 and assesses the impact of 
the first changes to the PBS pricing policies. The third such time period was from 2011 to 2013 and 
assesses the impact of the PBS reforms and PBS expenditure on statins. The individual drivers were 
assessed separately, including the use of statins, average PBS expenditure per statin prescription 
and the average strength of statins dispensed on the PBS. Cost driver analyses were conducted over 
calendar year periods to standardise all price, volume, inflation and population data sets that were 
available across consistent 12 month periods. 
 
x Use of statins (Volume and switch effect) 
Utilisation of all statins was calculated in DDD/1,000 inhabitants/day (DIDs), the international unit of 
drug utilisation [44, 45].  The DDD index for statins was changed in 2009 (the new DDD for 
atorvastatin was 20 mg instead of 10 mg, the new DDD for simvastatin was 30 mg instead of 15 mg) 
[46]. Analyses in the study used the 2009 DDDs across the entire study period to standardise the 
doses of statins [47, 48]. A sensitivity analysis was conducted using historical DDDs. The total 
population for each 12 month period was obtained from the Australian Bureau of Statistics [49]. Fixed 
dose combinations which contain statins were included in the overall utilisation analysis, as well as in 
a separate analysis of the fixed dose combinations market.  
 
x Monthly PBS expenditure per statin prescription (Price effect) 
For every month over the study period, PBS expenditure per prescription for each statin was 
calculated. There is a seasonal variability in the expenditure per prescription data due to the 
availability of the safety net for PBS prescriptions. This creates variability by month in the number of 
prescriptions dispensed and also in government expenditure on statins over the study period. 
Concession patients do not pay a co-payment for medicines when they reach the safety net, while 
general patients pay only the concession co-payment when they reach the safety net. Towards the 
end of each calendar year, patients who have reached the safety net tend to seek multiple supplies of 
their medicines at the cheaper cost to decrease out-of-pocket payments in the coming year. The 
Government subsidises a larger relative cost for patients on the safety net which can skew the 
analysis on expenditure per prescription. 
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x Interrupted time series analyses 
Interrupted time series analyses are used to study data that is collected at multiple points in time 
before and after an intervention to detect whether or not the intervention has had a significant impact 
on the underlying trend [50]. Segmented regression analyses were conducted on this data using 
regressions with autocorrelated errors to analyse the impact of PBS reforms and other pricing 
changes in the levels and trends in prices for all statins. These analyses are used to assess the 
slopes of two contiguous line segments before and after an intervention to determine whether there 
has been a statistically significant change in the slope. This method was used to provide a statistical 
test analysing the effect of PBS pricing policies on the expenditure per prescription for statins. The 
analyses were conducted for expenditure per prescription for each month, with the model taking into 
account the safety net effect. These analyses allow determination of whether the intervention had led 
to a statistically significant change in expenditure per prescription, but it was not possible to quantify 
the change. The analyses were conducted using SAS Enterprise Guide Version 5.1. 
 
The estimated base model for the regressions was: ௧ܻ ൌ ߚ଴ ൅ ߚଵݐ݅݉݁ ൅ ߚଶ݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊ ൅ ߚଷݐ݅݉݁݂ܽݐ݁ݎ݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊ 
Yt is the mean expenditure per prescription for the time period t, time is a continuous variable 
indicating time in months from the start of the study period, intervention is a dummy variable with time 
t occurring prior to the price change (value for intervention = 0) and after the price change (value for 
intervention = 1). Three change points were used in this study, August 2005, August 2007 and April 
2012, where changes to the price of statins on the PBS occurred due to implemented policies. 
 
Time series analyses are the strongest and most commonly used design to assess the impact of an 
intervention where a randomised control trial is not possible [50-52]. The analysis can be used to 
detect whether or not an intervention had a significantly greater effect than the underlying trend by 
comparing time trends before and after the intervention [50, 53, 54]. One of the weaknesses for 
interrupted time series analyses is that they require multiple data points to reduce the variability and 
outliers [55]. This weakness was counteracted by having monthly data points to decrease variability 
and confirm the presence of a trend. Other factors which may affect validity include outcome coding, 
co-interventions or changes to the population under study [56].  
 
x Strength effect 
Average strength per prescription for each statin dispensed was calculated by using the formula 
below: ܣݒ݁ݎܽ݃݁ݏݐݎ݁݊݃ݐ݄ ൌ ȭሺܰݑܾ݉݁ݎ݋݂݌ݎ݁ݏܿݎ݅݌ݐ݅݋݊ݏ݋݂݄݁ܽܿݏݐݎ݁݊݃ݐ݄ ൈ ܵݐݎ݁݊݃ݐ݄݋݂݌ݎ݁ݏܿݎ݅݌ݐ݅݋݊ሻܰݑܾ݉݁ݎ݋݂݌ݎ݁ݏܿݎ݅݌ݐ݅݋݊ݏ  
 
Results 
 
x Summary of events 
Simvastatin was the first statin listed on the PBS in 1990, followed by pravastatin in 1993 and 
fluvastastin in 1996 (Table 2). In 1998, atorvastatin was listed on the PBS on a cost-minimisation 
basis with simvastatin and pravastatin. As mentioned earlier, in July 2005 the listing was changed to 
cost-effectiveness on the basis that the PBAC concluded that atorvastatin was more effective than 
simvastatin in lowering LDL-cholesterol, justifying a relative price difference of 12.5% [36]. In 2006, 
rosuvastatin was the latest statin to be listed on the PBS - on a cost-minimisation basis with 
atorvastatin.  In 2012, a review of the scientific evidence on statin therapies concluded that the price 
differential of 12.5% was still acceptable [36]. However, at that time, the actual price differential was 
about 30% above the original price differential considered to be cost-effective because the prices of 
off-patent simvastatin and pravastatin had decreased [36].  
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Table 2 ± Summary of PBS status and prices of statins [36, 37].  
 
Date Event 
December 1990 Simvastatin first listed on PBS 
June 1993 Pravastatin first listed on PBS 
January 1996 Fluvastatin first listed on PBS 
January 1998 Atorvastatin first listed on PBS on a cost-minimisation basis with simvastatin and 
pravastatin 
(10mg atorvastatin = 20mg simvastatin = 20mg pravastatin) 
Statin therapeutic group established including atorvastatin, simvastatin and 
pravastatin 
December 2004 First generic brand of simvastatin listed on PBS 
January 2005 24% increase in patient co-payment 
July 2005 Atorvastatin listing changed from cost-minimisation to cost-effectiveness based 
on data showing atorvastatin being more effective than simvastatin in lowering 
LDL-cholesterol and a relative price difference of approximately 12.5% 
August 2005 12.5% price reduction applied to simvastatin and pravastatin due to new generic 
brands being listed 
December 2005 First generic brand of pravastatin listed on PBS 
February 2006 First fixed dose combination containing simvastatin PBS listed 
October 2006 Changes to eligibility for cholesterol lowering medicines including statins on the 
PBS to include patients with existing comorbidities 
December 2006 Rosuvastatin first listed on PBS on a cost-minimisation basis with atorvastatin 
(10mg rosuvastatin = 30mg atorvastatin) 
First fixed dose atorvastatin combination with amlodipine was listed 
First fixed dose simvastatin combination with ezetimibe was listed 
August 2007 20% price reduction to simvastatin offered by manufacturers, also applied to 
pravastatin via therapeutic groups  
August 2008 25% F2T price reductions for simvastatin and pravastatin due to high level of 
discounting in community 
September 2009 Higher potency statin therapeutic group established which contains atorvastatin 
and rosuvastatin 
April 2012 EAPD first cycle price reductions for simvastatin (55.6%) and pravastatin 
(49.94%) 
Statin therapeutic group containing simvastatin and pravastatin abolished 
First generic brand of atorvastatin listed on PBS 
16% mandatory price reduction for atorvastatin due to new brands being listed on 
the PBS 
16% price reduction for rosuvastatin due to therapeutic group with atorvastatin 
May 2012 Review of Statin Therapies report released after request made in the Senate 22 
November 2010 
December 2012 25 % price reduction to atorvastatin offered by manufacturers 
20.81% price reduction for rosuvastatin due to atorvastatin bench marking 
June 2013 First generic brands of rosuvastatin listed on PBS 
August 2013 Expanded and Accelerated Price Disclosure second cycle price reductions for 
simvastatin (44.66%) and pravastatin (34.08%) 
December 2013 Expanded and Accelerated Price Disclosure first cycle price reduction for 
atorvastatin (50.06%) 
 
x Total PBS expenditure on statins 
In real terms (2013 dollars), total PBS expenditure on statins was AUD 139.8 million in 1992 and 
increased to AUD 1,216.4 billion in 2010. PBS expenditure on statins decreased from 2011 onwards 
and accounted for AUD 645.6 million of total PBS expenditure in 2013 (Figure 1). In 2013, 
atorvastatin accounted for the greatest proportion of PBS statin expenditure, followed by rosuvastatin 
and simvastastin. 
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Figure 1 ± Total PBS expenditure on statins 1992 ± 2013 (in 2013 AUD) 
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Figure 2 ± Drivers of PBS statin expenditure 1992 to 2013 and three shorter periods
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x Drivers of statin expenditure 
 
Drivers of PBS statin expenditure from January 1992 to December 2013 
 
Over the whole study period, the largest driver was the increased quantity of statins dispensed on the 
PBS. The largest negative driver was the average expenditure per prescription on statins. This 
decreased as a result of an inflation-adjusted fall in the price of statins. There is no switching effect 
over the study period because simvastatin was the only statin available at the beginning of the study 
period. The other effect that was seen was the new statin effect which accounted for 1.9% of the total 
drivers increasing statin expenditure (Figure 2) 
 
Drivers of PBS statin expenditure from January 1997 to December 2005 
The growth overall in total PBS statin expenditure from 1997 and 2005 was predominantly explained 
by the increased volume of statins dispensed via the PBS. The next factor that impacted upon total 
expenditure increases over this time period was the increase in the strengths of the statins dispensed 
on the PBS, followed by the introduction of new statins on the PBS and then changes in the utilisation 
of statins. Over this period, the introduction of atorvastatin, and of new strengths of pravastatin and 
simvastatin on the market accounted for an increase of $19.0 million (AUD 2013) adjusted for inflation 
compared to the other statins. From 1997 to 2005, the cost of statins to the government decreased 
overall in real terms and was the only negative driver for expenditure, accounting for $106.4 million 
(AUD 2013). 
 
Drivers of PBS statin expenditure from January 2006 to December 2010 
From 2006 to 2010, the largest positive driver for PBS expenditure on statins was the increased 
quantity dispensed, accounting for $263.1 million (in 2013 AUD) overall in increased expenditure. The 
switch effect from cheaper statins with generics available on the PBS to more expensive patent 
protected statins was the second largest positive driver of PBS expenditure on statins, followed by the 
increased strengths dispensed for patients. In contrast, the entry of new statins on the PBS and the 
subsequent decrease in use of other statins and average Government expenditure were negative cost 
drivers over the period. 
 
Drivers of PBS statin expenditure from January 2011 to December 2013 
 
The sum of the effects driving down statin expenditure from 2011 to 2013 was a total of $563.5 million 
(AUD 2013) overall adjusted for inflation. The majority of the decrease in total statin expenditure was 
due to a decrease in prices ($473.2 million) and there was also a decrease in the volume of statins 
reimbursed ($133.7 million). Changes to the relative proportion of different statins dispensed and the 
strengths of statins reimbursed led to relatively small increases of AUD 22.9 million and AUD 20.5 
million (in AUD 2013) respectively. 
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x Use of statins 
From 1992 to 2012, there was a substantial and sustained increase in the total utilisation of statins on 
the PBS (from 3.59 DDD/1000/day in 1992 to 142.9 DDD/1000/day in 2012). This equates to a 
compounded annual growth rate of 20.2% over this period, and reflects both an introduction of new 
medicines on the PBS as well as increasing strengths prescribed to patients. In 2013, there was a 
decrease in the total utilisation of statins on the PBS of almost 17% (to 119.2 DDD/1000/day) (Figure 
3).  
 
When atorvastatin was originally listed on the PBS in 1998, it accounted for 23.7% of total statin 
utilisation in that calendar year. By 2013, atorvastatin and rosuvastatin accounted for 83.2% of total 
statin utilisation on the PBS. The total number of statin prescriptions which were subsidised by the 
PBS grew from 1.8 million prescriptions in 1992 to 25.3 million prescriptions in 2012. In 2013, there 
was a decrease of 18.2% for PBS subsidised statins (20.7 million prescriptions). Fluvastatin utilisation 
on the PBS has been lower than other statins. This may in part be due to fluvastatin being considered 
to be a statin with lower potency in addition to there being less data showing cardiovascular benefits 
compared to the other statins [57]. A sensitivity analysis was conducted on utilisation by substituting 
historical DDDs for each statin. This showed a higher trend for utilisation up to 2009, where utilisation 
for atorvastastin and simvastatin halved compared to the base case results (as their DDD doubled 
from 10mg to 20mg and from 15mg to 30mg respectively). Similarly, fluvastatin and pravastatin 
utilisation decreased in 2009 as their DDDs increased. 
 
Figure 3 ± Total utilisation of statins on the PBS (in year 2009 DDD/1000/day) 
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x Average PBS expenditure on statins between 1992 and 2013 
PBS expenditure per statin prescription increased for all statins from the first listing until 2005 (Figure 
4). There were three price reduction dates, the first in August 2005 (12.5% price reduction for 
simvastatin and pravastatin due to new generic brands being listed), the second in August 2007 (20% 
price reduction offered by manufacturers) and the third in April 2012 (around 50% price reduction for 
generic statins as the result of the first price disclosure cycle and 16% price reduction for atorvastatin 
and rosuvastatin due to new generic brands being listed).These events resulted in a statistically 
significant decrease in expenditure per prescription for simvastatin and pravastatin in 2012 vs. 2005 
(Table 3). Atorvastatin and rosuvastatin had one price reduction in April 2012 that resulted in a 
significant decrease to expenditure per prescription.  
 
Table 3 ± Slope changes of statin expenditure per prescription 
 August 2005 August 2007 April 2012 
Atorvastatin No significant change No significant change -1.183 (±0.126) 
p < 0.0001 
 
Fluvastatin No significant change No significant change No significant change 
 
 
Pravastatin -0.514 (± 0.041) 
p < 0.0001 
-0.572 (± 0.107) 
p < 0.0001 
-0.792 (± 0.313) 
p < 0.012 
 
Rosuvastatin N/A N/A -0.794(±0246) 
p = 0.002 
 
Simvastatin -0.523 (± 0.052) 
p < 0.0001 
-0.628 (±0.099) 
p < 0.0001 
-0.877 (±0.314) 
p = 0.0057 
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Figure 4 ± Monthly expenditure per PBS prescription (in 2013 AUD) 
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x Strength effect 
Throughout the study period, there was an increase in the average strength of each statin prescribed 
for patients in the community (Table 4). This reflected an increase in the relative number of 
prescriptions for higher doses of statins compared to lower doses over the study period. On average, 
the strength prescribed on the PBS for atorvastatin increased by a compound rate of 4.9% per 
annum, fluvastatin increased by 4.0% per annum, pravastatin increased by 5.4% per annum, 
rosuvastatin increased by 3.2% per annum and simvastatin increased by 5.4% per annum1.  
 
Table 4 ± Average strength of statin dispensed on PBS (mg/prescription) 
 
 Simvastatin Pravastastin Fluvastatin Atorvastatin Rosuvastatin 
1992 13.0     
1993 13.2 12.9    
1994 13.2 13.2    
1995 13.5 14.2    
1996 14.1 15.4 25.0   
1997 15.1 16.5 27.1   
1998 16.7 19.6 28.0 17.3  
1999 18.3 22.5 28.5 18.6  
2000 21.3 25.2 29.4 19.6  
2001 23.8 26.8 30.1 20.6  
2002 26.0 28.4 30.6 23.0  
2003 28.4 29.8 31.0 24.9  
2004 30.5 30.7 31.5 27.0  
2005 32.1 31.4 32.0 29.2  
2006 33.7 33.8 32.8 30.8 12.4 
2007 35.2 35.5 32.8 31.9 13.4 
2008 36.6 36.6 40.0 32.7 14.1 
2009 38.0 37.8 44.5 33.4 14.5 
2010 39.1 38.2 45.9 34.0 14.7 
2011 39.6 38.5 47.2 34.3 14.9 
2012 39.1 37.8 47.9 34.6 14.9 
2013 38.9 37.2 48.8 35.5 15.5 
 
  
                                                          
1 Compound percentage formula applied across time period where ܵଶ଴ଵଷ ൌ ௧ܵሺ ? ൅ ݔሻሺଶ଴ଵଷି௧ሻ where S2013 is the 
strength of statin in 2013, St is the strength of statin in the year of first prescription and x is the compound 
percentage increase. 
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Discussion 
 
PBS expenditure on statins has been a major contributor to the overall increase in PBS expenditure in 
recent years. Total PBS expenditure in the financial year ending in 2003 was $4.6 billion nominally 
($5.9 billion in 2013 dollars), compared to $9.0 billion in 2013 [9, 10]. PBS expenditure accounted for 
0.59% and 0.58% of GDP in 2003 and 2013 respectively. The major driver for the increase in PBS 
expenditure for statins was the increased volume that was dispensed to patients through the PBS. 
The major negative driver that decreased statin expenditure over the study period was the average 
Government expenditure per prescription for statins. The secondary drivers that increased total PBS 
statin expenditure included increased strengths of statins dispensed and the choice of patent 
protected statins. The average Government expenditure per statin prescription has decreased with 
the implementation of new pricing policies since 2005 (Figure 4). 
 
x Increased volume of statins 
As would be anticipated, the largest driver of statin expenditure over the majority of the study period 
was the increased volume of statins dispensed on the PBS. This is similar to some European 
countries, as the uptake of statins to treat high cholesterol levels increased [8, 14, 17, 58-60]. Whilst 
volumes decreased in 2012 and 2013, the considerable growth in statin utilisation from 1992 to 2011 
contributed to an appreciable increase in statin expenditure on the PBS from 1992 to 2011. Overall 
from 1992 to 2012, utilisation of statins on the PBS increased from 3.6 DDD/1000/year to 119.2 
DDD/1000/year (Figure 3).  
 
There have been questions raised about the appropriateness of statin prescribing in the community, 
where there has likely been an over-prescribing of statins to low-risk patients [61]. In the UK, statins 
have been shown to be cost-effective in secondary prevention compared to other treatment options 
[62]. In primary prevention, the cost-effectiveness ratios are dependent on a number of risk factors but 
still support aggressive treatment recommendations [63]. In the US, using low cost statins is cost-
effective for most patients with even modestly elevated cholesterol or coronary heart disease risk 
factors [62]. These studies suggest that the large utilisation of statins may lead to improved health 
outcomes for patients in the future. However, limited population-based data are available to assess 
the actual impact of statins on health outcomes in Australia and there may be diminishing returns.   
 
There was a decrease in the total volume of statins dispensed on the PBS from 2011 onwards. One 
factor was the increasing number of prescriptions that fall under the general co-payment level and 
thus do not attract a Government subsidy. The price of some simvastatin and fluvastatin strengths 
first fell below the general co-payment in 2005, pravastastin in 2007, and atorvastatin and 
rosuvastatin in 2012. These medicines are typically fully funded by patients, with the Government only 
subsidising the cost of medicines for general and concession patients who reach the safety net. An 
increasing µunder co-payment¶ market for statins should lead to further decreases in total government 
spending for statins in the future. In the financial year 2012-13, under co-payment utilisation for statins 
was 3.3% of the total [64]. This increased to 7.5% of total statin utilisation in 2013-14 [65].  
 
x The price of statins 
For all statins listed on the PBS, the average Government expenditure per PBS prescription after 
adjusting for inflation increased every year from the time they were listed up to 2005. Starting in 2005, 
the changes to the PBS pricing policies have been successful in reducing the average statin 
expenditure  on the PBS [28, 66]. The implementation of the PBS reforms in 2007 led to the largest 
decrease in the average statin expenditure to the Government. In 2012-13, the decrease in the price 
of statins on the PBS was the prime driver of decreased expenditure, accounting for AUD$441.9 
million in savings compared to the years prior to this. 
 
However, there remain inefficiencies in the current PBS pricing policies, especially with regard to the 
extent of the initial price reductions and the length of time taken for price disclosure to become 
effective in reducing the prices of statins. The initial price reduction of only 16% on first listing of a 
generic on the PBS is lower than in other countries including France (55% price reduction) and 
Austria (48% price reduction for the first generic and 60% by the third generic) and, as previously 
mentioned, prices of generic simvastatin are only 2% to 4% of the prices prior to patent expiry in 
Netherlands, Sweden and the UK [17, 19, 67, 68]  The initial price reduction effectively caps the 
savings for the PBS at this 16% level until price disclosure cycles are applied to these medicines.  
This appears inefficient compared to policies in other countries to rapidly lower generic prices, e.g. 
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Sweden, enhanced by the recent instigation of monthly auctions to further lower generic prices [19, 
69, 70]. 
 
Medicines are PBS-listed on the basis of cost-effectiveness or cost minimisation compared to the 
existing medicine that would have been most likely to be prescribed. In 2005, the prices for 
simvastatin and pravastatin decreased while the prices for atorvastatin and rosuvastatin did not as 
they were listed in the F1 formulary, which insulated them from any price changes that may occur in 
the F2 formulary (which includes products with a generic available) [71]. There are no policies to 
maintain the incremental cost-effectiveness ratio when generic analogues of comparator medicines 
are introduced onto the PBS. The breakdown of reference pricing was noticeable in the case of the 
statins. The price differences between the presumed higher potency statins (atorvastatin and 
rosuvastatin) compared to simvastatin and pravastatin were not indicative anymore of the incremental 
cost-effectiveness ratios as calculated by the PBAC originally. This increase in the incremental cost-
effectiveness ratio of atorvastatin compared to simvastatin raises the question as to whether 
atorvastatin still remained cost-effective at the higher price compared to simvastatin. The incremental 
cost-effectiveness ratio would be even greater if prices for simvastatin were at levels observed in the 
Netherlands, Sweden and the UK once generic simvastatin became available [8, 14, 17].  
 
Part of the problem with obtaining low prices for generics in Australia is an operational time lag 
between the initial price reduction due to the listing of generics and price reductions due to price 
disclosure. In the case of atorvastatin, the first price reduction due to price disclosure occurred more 
than 20 months after the introduction of generic atorvastatin on the PBS. Price disclosure is a process 
that calculates price discounts available in the wholesale market and applies them to the PBS price. 
Because this occurs after the prices appear in the market, there is a lag time where the PBS price is 
more expensive than the wholesale price [72]. Interestingly, in April 2014, the PBS adopted a shorter 
period of time between price disclosure cycles to revise the prices of medicines twice a year as 
opposed to once a year as had been the case, but the time lag can still lead to missed savings [72]. 
However, even when allowing for this, prices of generic statins appear appreciably higher than in the 
Netherlands, Sweden and the UK.  
 
Another factor which led to decreases in government spending on statins is patient co-payment. In 
Australia, the co-payment is increased every year in line with inflation, except in 2005 when the co-
payment was increased by 24%. Increases in patient co-payment and decreasing prices of medicines 
due to PBS pricing policies have led to an increase in the number of medicines which fall into the 
µunder co-payment µmarket as shown by the decrease in total utilisation and government expenditure 
on statins in 2013. However, co-payment increases may have an impact on the SDWLHQW¶VDELOLW\WR
afford medicines and thus may have an adverse effect on the SDWLHQW¶VKHDOWK[73].  
 
Conversely, lower co-payments enhance patient adherence across disease categories including 
statins to improve future care [23, 74, 75]. Patient co-payments could be appreciably reduced in 
Australia if policies were implemented to obtain lower prices for generics and enhance their utilisation 
compared to patented statins, as seen among a number of European countries [8, 14, 17, 22]. 
 
x Use of patent-protected statins 
In December 2004, simvastatin was the first statin to lose patent protection, followed by pravastatin in 
December 2005. The preferential use of the new, patented, statins atorvastatin and rosuvastatin with 
higher prices was the second major reason for the increase in total statin expenditure on the PBS 
from 1998 to 2011. This may have been aided by comments from the PBAC endorsing the prescribing 
of atorvastatin and rosuvastatin on the basis that atorvastatin and rosuvastatin had been shown to be 
more effective in reducing LDL-cholesterol levels [36].  However, other sources have claimed that 
there is no strong evidence that these statins are better than simvastatin or pravastatin in improving 
population health outcomes by reducing cardiovascular morbidity [20, 21, 76-78]. Australian clinical 
guidelines have never specified that one statin should be used in preference to another in the 
treatment of hypercholesterolemia to prevent cardiovascular events [79-81]. We are not aware of any 
research conducted to determine whether Australian prescribers follow these guidelines when 
prescribing statins. However, the increase in the volume of statins prescribed over the study period 
shows that the management of dyslipidemia in patients is highly prevalent in Australia. 
 
Other factors may also affect the utilisation of the more expensive statins on the PBS. Interactions 
between the pharmaceutical industry and prescribers may influence prescribing habits and the choice 
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of therapy for patients [82]. Concern has been raised about the role of manufacturers in promoting the 
use of patent-protected medicines at a time when off-patent medicines are available to the market, 
coupled with the fact that probably the only companies marketing to physicians are those with 
patented products [83]. A similar high rate of atorvastatin and rosuvastatin utilisation versus generic 
statins was seen in Ireland where there are few demand-side measures compared with those 
European countries having multiple measures to encourage the preferential prescribing of generic 
over patented statins [8, 14, 17, 22, 84]. Cost-effectiveness is an important factor that is taken into 
consideration when medicines are initially listed on the PBS. Beyond this initial consideration, it is 
arguable that cost-effectiveness is not a prominent feature of the culture of medicines use in Australia. 
Educating and incentivising prescribers to use cheaper and more cost-effective medicines might lead 
to long term savings on medicines expenditure. Providing incentives for prescribers to preferentially 
prescribe cheaper off-patent medicines could also lead to substantial savings to the Australian health 
care system.  
 
The role of pharmacists in promoting the use of off-patent medicines is influenced by co-payment 
levels and the price they can negotiate for generic medicines. Pharmacies can negotiate positive 
trading terms for generic medicines compared to originator brands, which presents them with a 
financial incentive to substitute generic medicines [85]. The maximum price that patients pay for 
medicines is set at the co-payment. However, there are brand price premiums for originator brands of 
simvastatin and pravastatin, where patients have to pay more for these originators.  
The reimbursement price that the Government pays for medicines is the same regardless of whether 
a medicine is generic or an originator brand.  Creating a reimbursement price difference for the 
Government, or providing a price incentive for patients to purchase generic medicines, could be 
beneficial for reducing PBS pharmaceutical expenditure and increasing utilisation of generic 
medicines. 
 
x Strength of statins 
Another finding was the increasing prescribing of higher strengths of statins over time (Table 3), 
potentially reflecting the implementation of clinical guidelines suggesting tighter cholesterol control for 
patients [81]. Prescribed doses of statins have been found to vary considerably across countries. In a 
recent cohort study in Finland, patients prescribed statins for the first time were typically initiated with 
either 10mg or 20mg simvastatin (94% of the cohort) [86]. In addition, a considerable proportion of 
patients initiated on statin therapy with less potent doses remained at the initial dose after 1 year. This 
suggested underdosing was common, even among patients with high cardiovascular risk [86]. Similar 
findings were seen in Ireland, the Netherlands and the Stockholm Metropolitan Healthcare Region, 
Sweden, with the average dose of simvastatin prescribed for secondary prevention in Ireland at 22mg 
[19, 87]. In the Netherlands, many patients have been prescribed starting doses at just over 15mg of 
simvastatin [88]. However, this is changing with recent guidelines advocating patients be started on 
higher strength statins with subsequent monitoring of prescriptions [17]. In Stockholm, the average 
prescribed dose of simvastatin was 20.4mg, with an appreciable proportion of patients prescribed only 
10mg simvastatin [8, 19]. There was also variable dosing of statins among the different regions in 
Norway as well as among insured populations in South Africa [89, 90]. On the other hand, there has 
been an appreciable increase in the prescribing of higher strength statins in the UK following the 
publication of studies such as the Heart Protection Study guidelines advocating 40mg simvastatin as 
well as physicians being incentivised to treat patients according to agreed lipid levels [8, 91]. 
 
x Limitations 
Some limitations should be recognised. Applying the driver methodology across the 1992 to 2013 
period leads to cross effects which can influence the results. Whilst each driver is analysed 
separately, there are cross effects due to the presence of two or more drivers. The large change in 
both volume and price when comparing 2013 to 1992 has led to large cross effects which are not 
presented as they do not represent the effect of an individual driver. However, these cross effects 
may have an impact on the overall analysis of drivers.  
 
By segregating each effect separately, this study tries to quantify the true effect of each driver while 
acknowledging that cross effects also have an impact on the changes in PBS expenditure on statins. 
Furthermore, the under co-payment market was not included. Under co-payment medicines are 
cheaper than those subsidised on the PBS and tend to contain lower strength statins. However, the 
under co-payment market represents a small proportion of total statin utilisation and does not have a 
large impact on Government expenditure. The under co-payment accounted for 3.3% and 7.5% of 
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total utilisation for statins in Australia in 2012-13 and 2013-14 respectively [64, 65]. The under co-
payment market for statins should increase in the future as price disclosure continues to drive down 
the reimbursement price for statins. This should lead to decreased Government spending on less 
expensive statins as their cost is borne by patients. 
 
Utilisation data were taken from publicly available PBS Item Reports which count services and not 
tablets dispensed. However, the same measure of services is used for comparisons over the study 
period. Patients who purchase statins through the PBS do not necessarily take their medicines but 
this could not be taken into account in this study. 
 
Conclusion 
 
In Australia, the increase in inflation-adjusted statin expenditure over time has been a result of 
increased utilisation generally, increased relative utilisation of more expensive statins and increased 
strengths prescribed to patients. This increased expenditure on statins has been counteracted by an 
inflation-adjusted decrease in the price of statins on the PBS over the study period. While there is still 
scope for greater price reductions, the changes to the PBS pricing policies have decreased the prices 
of generic medicines in recent years. Limitations on the power of policies to support the use of generic 
statins over patented statins may have contributed to excess expenditure. Demand side policies 
encouraging the utilisation of cheaper medicines which deliver the same health outcomes as their 
more expensive alternatives should be a priority. This should increase value for money on the PBS 
and lead to savings within the health budget, which could be reallocated to other important areas of 
health care. 
 
Key issues 
 
x Statins are the class with the highest utilisation and expenditure in Australia.  
x The major driver for increased expenditure on statins in Australia was increased utilisation, 
followed by the relative utilisation of more expensive statins and increasing strengths of statins 
dispensed.  
x When adjusted for inflation, expenditure per prescription of statins in Australia was the major 
negative driver for total expenditure.  
x Pricing policies introduced in Australia have been effective in reducing the prices paid for generic 
medicines. Total expenditure on statins has decreased in recent years as a result of decreases to 
the prices for statins that have lost patent protection; however, expenditure on statins would have 
been appreciably lower in Australia with prices of generic statins similar to those seen in some 
European countries 
x The utilisation of patent protected statins shows one example of utilisation of newer and more 
expensive medicines leading to higher total expenditure. This can be addressed through 
measures to encourage the preferential prescribing of generic statins first line 
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